Scientists use magnetic nanotech to safely rewarm frozen tissues for transplant

17-Sep-2024 - Every day, people die waiting for an organ transplant. Time is at a premium, not just for those awaiting organs, but also for the organs themselves, which can deteriorate rapidly during transportation. Looking to extend the viability of human tissues, researchers report in ACS’ Nano Letters their ...

HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration

Elias Papatheodorou moves from Chair of the Board to CEO of HepaRegeniX

15-Jul-2024 - HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapies for the treatment of acute and chronic liver diseases, announced the closing of a Series C round led by Vesalius Biocapital IV with participation of existing investors Novo Holdings, Boehringer Ingelheim Venture ...

Millions in funding to revolutionize immunotherapy

Swiss start-up NXI Therapeutics extends pre-seed financing to CHF 3.5 million in run-up to larger seed financing

25-Jun-2024 - NXI Therapeutics AG, developer of tomorrow’s disruptive immunotherapies by coronin 1 modulation, announces the extension of a pre-Seed financing totalling to 3.5 million CHF. This financing extension comes in the run-up to a larger Seed financing that the company is currently raising. Kickfund ...

Memo Therapeutics increases Series C financing to CHF 45 million

Proceeds will be used to expand Phase II of best-in-class anti-BK Virus antibody to become the largest study ever conducted for BK virus infection in kidney transplantation

21-May-2024 - Memo Therapeutics AG (or “MTx”) announces that it has successfully raised CHF 20 million as part of an extension of its Series C financing, bringing the total amount raised in the funding round to CHF 45 million. The new funding will be used to bolster the clinical advancement of MTx’s lead ...

Revolution in blood donation? Enzymes open new path to universal donor blood

Researchers have discovered enzymes that remove hindrances that stood in the way of developing universal donor blood

03-May-2024 - The quest to develop universal donor blood has taken a decisive step forward. Researchers at Technical University of Denmark (DTU) and Lund University have discovered enzymes that, when mixed with red blood cells, are able to remove specific sugars that make up the A and B antigens in the human ...

Keeping organ rejection in check with killer cells

Therapeutic potential not only for transplant medicine

06-Dec-2023 - A donated organ always remains foreign to the body and is fought against by the immune system. In order to prevent rejection, the entire immune defence must be suppressed for a lifetime. An MHH research team is now using genetically modified killer cells against precisely those immune cells that ...

Verici DX reaches a global licensing and commercialisation agreement with Thermo Fisher Scientific

Agreement grants rights to further develop an assay for pre-transplant prognostic testing

20-Nov-2023 - Verici Dx plc, a developer of advanced clinical diagnostics for organ transplant, announced that it has signed an exclusive global licensing agreement with Thermo Fisher Scientific to further develop an assay for pre-transplant prognostic testing for risk of early kidney rejection. The exclusive ...

TolerogenixX revolutionises kidney transplantation

TolerogenixX expands Phase II immune-tolerance trial and closes EUR 12 million Series A financing

12-Jul-2023 - TolerogenixX GmbH, a biopharmaceutical company developing personalized cellular therapies aimed at achieving sustained immune tolerance to combat organ rejection and autoimmune diseases, announced that in the TOL2- Phase IIb study in renal transplant patients TolerogenixX has received green light ...

Pigs as Organ Donors

New Findings on the Prevention of Retrovirus Infections

22-Mar-2023 - Intensive research is being carried out to enable the transplantation of organs from specially bred pigs to humans. However, the pig genome contains the genomes of various endogenous retroviruses (PERV-A, B and C) that could potentially cause infectious diseases. A research team at the ...

Start-up NextImmune supported by Venture Kick

Development of selective immunosuppressive drugs

05-Jul-2022 - NextImmune, a spin-off from the Biozentrum of the University of Basel, has received financial support of 150,000 Swiss francs from the Venture Kick funding initiative. The start-up develops a new generation of immunosuppressive drugs for autoimmune diseases and organ transplantation. The company ...